Goldman Sachs’s Akero Therapeutics AKRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-855,766
Closed -$40.6M 6423
2025
Q3
$40.6M Buy
855,766
+90,025
+12% +$4.36M 0.01% 1599
2025
Q2
$40.9M Buy
765,741
+277,349
+57% +$12.6M 0.01% 1491
2025
Q1
$19.8M Buy
488,392
+30,868
+7% +$1.31M ﹤0.01% 2040
2024
Q4
$12.7M Sell
457,524
-204,797
-31% -$6.2M ﹤0.01% 2566
2024
Q3
$19M Sell
662,321
-120,629
-15% -$3.14M ﹤0.01% 2114
2024
Q2
$18.4M Buy
782,950
+193,098
+33% +$4.13M ﹤0.01% 1957
2024
Q1
$14.9M Sell
589,852
-23,423
-4% -$563K ﹤0.01% 2097
2023
Q4
$14.3M Buy
613,275
+282,190
+85% +$5.57M ﹤0.01% 2202
2023
Q3
$31.2M Buy
331,085
+122,042
+58% +$5.68M 0.01% 1426
2023
Q2
$9.76M Sell
209,043
-14,248
-6% -$653K ﹤0.01% 2481
2023
Q1
$8.54M Buy
223,291
+37,379
+20% +$1.67M ﹤0.01% 2564
2022
Q4
$10.2M Sell
185,912
-1,932,885
-91% -$82.8M ﹤0.01% 2570
2022
Q3
$72.1M Buy
2,118,797
+255,193
+14% +$3.9M 0.02% 861
2022
Q2
$0 Buy
1,863,604
+770,924
+71% +$8.04M ﹤0.01% 6429
2022
Q1
$15.5M Sell
1,092,680
-674,034
-38% -$11.8M ﹤0.01% 2270
2021
Q4
$37.4M Buy
1,766,714
+1,735,530
+5,565% +$38.5M 0.01% 1584
2021
Q3
$697K Buy
31,184
+2,610
+9% +$59.1K ﹤0.01% 4996
2021
Q2
$709K Sell
28,574
-180,853
-86% -$5.08M ﹤0.01% 5002
2021
Q1
$6.08M Sell
209,427
-40,278
-16% -$1.22M ﹤0.01% 2963
2020
Q4
$6.44M Buy
249,705
+187,947
+304% +$5.23M ﹤0.01% 2821
2020
Q3
$1.9M Sell
61,758
-9,013
-13% -$315K ﹤0.01% 3606
2020
Q2
$1.76M Buy
70,771
+16,108
+29% +$368K ﹤0.01% 3546
2020
Q1
$1.16M Buy
54,663
+17,777
+48% +$381K ﹤0.01% 3653
2019
Q4
$819K Buy
36,886
+10,762
+41% +$223K ﹤0.01% 4236
2019
Q3
$594K Sell
26,124
-32,040
-55% -$746K ﹤0.01% 4361
2019
Q2
$1.11M Buy
+58,164
New +$1.1M ﹤0.01% 3927

Other funds holding AKRO